ZENEREI Institute (ZENEREI, LLC) is a private research center and contract research organization (CRO) dedicated to developing and marketing innovative neurophenotyping techniques, including high-throughput drug/small molecule screening using aquatic zebrafish (Danio rerio) models.
Our technology benefits clients by increasing the accuracy and efficiency of their drug screening programs and/or experimental model development, reducing the time and cost of discovery work and increasing the success rate, which involves moving the best drug candidates from screening to preclinical development. Overall, we get our clients' products to clinical trial (and to the market) sooner at far less cost vs. traditional rodent-based development.
ZENEREI is a CRO which offers enhanced behavioral analyses and tools, as well as sensitive drug and small molecule screens and pathology-related experimental model development for a broad range of scientific fields, including biotechnology, pharmacology, genetics and neuroscience. Our team has over 20 years of experience in translational animal research, and is sensitive to the needs of other biomedical researchers. In addition to screening compounds or mutants, we will make test recommendations and assist to design experiments to ensure the viability and correct interpretations of the results.
Depression is a serious psychiatric condition affecting millions of patients worldwide. Unipolar depression is characterized by low mood, anhedonia, social withdrawal and other severely debilitating psychiatric symptoms. Bipolar disorder manifests in alternating depressed mood and 'hyperactive' manic/hypomanic states. Due to their high throughput value, genetic tractability, low cost and quick reproductive cycle, zebrafish have emerged as a promising new model species for studying brain disorders. We recognize the developing utility of zebrafish for studying depression disorders, as well as for anti-depressant drug discovery.
ZENEREI offers several tests for analyzing zebrafish depression-related states and their sensitivity to a wide range of depression-active drugs
Autism spectrum disorder (ASD) is a serious neurodevelopmental disorder with complex symptoms and unclear pathogenesis. The conserved nature of social behavior and its molecular pathways suggests that alternative zebrafish models can be developed to complement and enhance ASD paradigms. Zebrafish are highly social animals, and can be used to study normal and pathological social behaviors. In fact, zebrafish spend the majority of their time (nearly 90%) swimming in groups (shoals) within 1-body length from each other.
ZENEREI offers a large battery of well established tests for analyzing zebrafish social and aggressive behaviors.
Cognitive impairment is a common symptom in multiple brain disorders. Therefore, predictive and high-throughput animal models of cognition and behavior are becoming increasingly important in the field of translational neuroscience research. Reliable models of the cognitive deficits characteristic of numerous neurobehavioral disorders, such as Alzheimer's disease and schizophrenia, have become a significant focus of investigation. Zebrafish are gaining popularity as an excellent model to study cognitive phenotypes, as well as to search for novel cognitive enhancers and neuroprotective mechanisms.
ZENEREI offers a large battery of well established tests for analyzing zebrafish memory and learning:
Anxiety is a prominent phenotype in zebrafish, and can markedly affect the results of in vivo experiments. Zebrafish anxiety tests can be used to screen anxiolytic and anxiogenic effects of various drugs.
Like anxiety, post-traumatic stress disorder (PTSD) represents a serious societal and public health concern. Given the clinical complexity of these disorders, greater investigation into candidate biomarkers and specific genetic
pathways implicated in both risk and resilience to stress is critical. Recent evidence shows a rapidly
increasing potential of zebrafish as models of anxiety and PTSD, and may further aid researchers in uncovering novel treatments and therapies.
ZENEREI offers a large battery of well established tests for analyzing anxiety-like and PTSD-like behavior in zebrafish.
Analyses of general motor function is thefirst necessary step for phenotyping genetically modified animals and screening various compounds. Because many behavioral tests in zebrafish can be confounded by alterations in locomotor activity, this domain must be carefully assessed in zebrafish studies. Aberrant locomotion can also be an important neurological phenotype relevant to a wide range of CNS disorders. ZENEREI offers several tests for analyzing locomotor activity in zebrafish, including adult zebrafish high-throughput screens and general motor phenotype assessment:
ZENEREI performs a wide range of neurophenotyping services, from single acute drug testing to running chronic studies as well as applying complex batteries of various tests. We combine in-depth behavioral screening with a parallel assessment of physiological biomarkers. Our analyses are organized based on major neurophenotypic domains:
Adult Zebrafish CNS and Toxicology Screening Core has not received any reviews.
Adult Zebrafish CNS and Toxicology Screening Core has not received any endorsements.